Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Pancreatic Neoplasms

abstract

  • The MTD of gemcitabine when combined with 5-FU via PVI on this schedule was 1,000 mg/m2/ wk; however, on the basis of administered dose-intensity, the recommended dose for additional investigation is 900 mg/m2. This combination chemotherapy regimen was well tolerated and showed promising antitumor activity in the treatment of pancreatic cancer.

publication date

  • February 1999

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10080603

Additional Document Info

start page

  • 585

end page

  • 92

volume

  • 17

number

  • 2